331366

594-01656-16

1

23

25

Proposed Committee Substitute by the Committee on Fiscal Policy (Appropriations Subcommittee on Health and Human Services)

A bill to be entitled

2 An act relating to an infectious disease elimination 3 pilot program; creating the "Miami-Dade Infectious 4 Disease Elimination Act (IDEA)"; amending s. 381.0038, 5 F.S.; authorizing the University of Miami and its 6 affiliates to establish a sterile needle and syringe 7 exchange pilot program in Miami-Dade County; 8 establishing the pilot program criteria; providing 9 that the possession, distribution, or exchange of 10 needles and syringes under the pilot program is not a 11 violation of the Florida Comprehensive Drug Abuse 12 Prevention and Control Act or any other law; providing 13 conditions under which a pilot program staff member, 14 volunteer, or participant may be prosecuted; requiring 15 the pilot program to collect certain data; prohibiting the collection of personal identifying information 16 from program participants; prohibiting state, county, 17 18 or municipal funds from being used to operate the 19 pilot program; requiring the pilot program to be 20 funded through private grants and donations; providing for expiration of the pilot program; providing for 21 2.2 severability; providing an effective date.

24 Be It Enacted by the Legislature of the State of Florida:

26 Section 1. <u>This act may be cited as the "Miami-Dade</u> 27 Infectious Disease Elimination Act (IDEA)."

Page 1 of 5

331366

594-01656-16 28 Section 2. Section 381.0038, Florida Statutes, is amended 29 to read: 381.0038 Education; sterile needle and syringe exchange 30 pilot program.-The Department of Health shall establish a 31 32 program to educate the public about the threat of acquired 33 immune deficiency syndrome. 34 (1) The acquired immune deficiency syndrome education 35 program shall: 36 (a) Be designed to reach all segments of Florida's 37 population; 38 (b) Contain special components designed to reach non-39 English-speaking and other minority groups within the state; 40 (c) Impart knowledge to the public about methods of 41 transmission of acquired immune deficiency syndrome and methods 42 of prevention; 43 (d) Educate the public about transmission risks in social, 44 employment, and educational situations; (e) Educate health care workers and health facility 45 46 employees about methods of transmission and prevention in their 47 unique workplace environments; 48 (f) Contain special components designed to reach persons 49 who may frequently engage in behaviors placing them at a high 50 risk for acquiring acquired immune deficiency syndrome; (g) Provide information and consultation to state agencies 51 52 to educate all state employees; and 53 (h) Provide information and consultation to state and local 54 agencies to educate law enforcement and correctional personnel 55 and inmates; -

(i) Provide information and consultation to local

56

331366

594-01656-16

57 governments to educate local government employees;-

58 (j) Make information available to private employers and 59 encourage them to distribute this information to their 60 employees: $\overline{\cdot}$

(k) Contain special components which emphasize appropriate
behavior and attitude change; and.

(1) Contain components that include information about
domestic violence and the risk factors associated with domestic
violence and AIDS.

(2) The <u>education</u> program designed by the Department of
Health shall <u>use</u> utilize all forms of the media and shall place
emphasis on the design of educational materials that can be used
by businesses, schools, and health care providers in the regular
course of their business.

(3) The department may contract with other persons in the design, development, and distribution of the components of the education program.

74 (4) The University of Miami and its affiliates may 75 establish a single sterile needle and syringe exchange pilot 76 program in Miami-Dade County. The pilot program may operate at a 77 fixed location or through a mobile health unit. The pilot 78 program shall offer the free exchange of clean, unused needles 79 and hypodermic syringes for used needles and hypodermic syringes 80 as a means to prevent the transmission of HIV, AIDS, viral 81 hepatitis, or other blood-borne diseases among intravenous drug 82 users and their sexual partners and offspring.

83

(a) The pilot program must:

84 <u>1. Provide for maximum security of exchange sites and</u> 85 <u>equipment, including an accounting of the number of needles and</u>

331366

594-01656-16

| 86 | syringes in use, the number of needles and syringes in storage, |
|-----|--|
| 87 | safe disposal of returned needles, and any other measure that |
| 88 | may be required to control the use and dispersal of sterile |
| 89 | needles and syringes. |
| 90 | 2. Operate a one-to-one exchange, whereby the participant |
| 91 | shall receive one sterile needle and syringe unit in exchange |
| 92 | for each used one. |
| 93 | 3. Make available educational materials; HIV, AIDS, and |
| 94 | viral hepatitis counseling and testing; referral services to |
| 95 | provide education regarding the transmission of HIV, AIDS, viral |
| 96 | hepatitis, and other blood-borne diseases; and drug abuse |
| 97 | prevention and treatment counseling and referral services. |
| 98 | (b) The possession, distribution, or exchange of needles or |
| 99 | syringes as part of the pilot program established under this |
| 100 | subsection is not a violation of any part of chapter 893 or any |
| 101 | other law. |
| 102 | (c) A pilot program staff member, volunteer, or participant |
| 103 | is not immune from criminal prosecution for: |
| 104 | 1. The possession of needles or syringes that are not a |
| 105 | part of the pilot program; or |
| 106 | 2. The redistribution of needles or syringes in any form, |
| 107 | if acting outside the pilot program. |
| 108 | (d) The pilot program must collect data for annual and |
| 109 | final reporting purposes, which must include information on the |
| 110 | number of participants served, the number of needles and |
| 111 | syringes exchanged and distributed, the demographic profiles of |
| 112 | the participants served, the number of participants entering |
| 113 | drug counseling and treatment, the number of participants |
| 114 | receiving testing for HIV, AIDS, viral hepatitis, or other |
| | I |

331366

594-01656-16

I

| 115 | blood-borne diseases, and other data deemed necessary for the |
|-----|--|
| 116 | pilot program. However, personal identifying information may not |
| 117 | be collected from a participant for any purpose. |
| 118 | (e) State, county, or municipal funds may not be used to |
| 119 | operate the pilot program. The pilot program shall be funded |
| 120 | through grants and donations from private resources and funds. |
| 121 | (f) The pilot program shall expire July 1, 2021. |
| 122 | Section 3. If any provision of this act or its application |
| 123 | to any person or circumstance is held invalid, the invalidity |
| 124 | does not affect other provisions or applications of the act |
| 125 | which can be given effect without the invalid provision or |
| 126 | application, and to this end the provisions of this act are |
| 127 | severable. |
| 128 | Section 4. This act shall take effect July 1, 2016. |